Aktie A3DJED QSAM BIOSCIENCES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen QSAM Biosciences, Inc.

Aktien

A3DJED

US74738N2027

QSAM

Schlusskurs OTC Markets
Andere Börsenplätze
 00:00:00 02.05.2024 		% 5 Tage % 1. Jan.
8,3 USD +7,10 % Intraday Chart für QSAM Biosciences, Inc. +3,75 % +36,07 %
03.05. Telix Pharmaceuticals (Us) Inc. hat die Übernahme von QSAM Biosciences, Inc. (OTCPK:QSAM) von Checkmate Capital Group LLC, Strategic Planning Assets Limited und anderen abgeschlossen. CI
20.03. QSAM Biosciences, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.
QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
Telix Pharmaceuticals Limited signed a non-binding term sheet to acquire QSAM Biosciences, Inc. for $33.1 million.
QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
QSAM Biosciences, Inc. announced that it has received $0.600001 million in funding
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities (form 8-K)
QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®
QSAM Biosciences, Inc. Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®
QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center
QSAM Biosciences Expands Its Study of Cyclosam(R) in the Treatment of Bone Cancer; Opens Patient Enrollment At Key Chicago Center, Insight Hospital and Medical Center
QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®
QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
QSAM Biosciences, Inc. Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam
QSAM BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DJED Aktie
  4. Nachrichten QSAM Biosciences, Inc.
  5. Andere Sprachen